New Zealand markets closed

NVS Jan 2025 100.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
11.400.00 (0.00%)
As of 01:03PM EDT. Market open.
Full screen
Loading interactive chart…
  • Zacks

    Pharma Stock Roundup: JNJ, NVS Q2 Earnings, RHHBY's Positive Obesity Pill Data

    J&J (JNJ) and Novartis (NVS) beat estimates for earnings and sales. Roche's (RHHBY) oral weight loss GLP-1 therapy achieves positive results in an early-stage study.

  • Investor's Business Daily

    Novartis Dives After Handing Amgen, Bristol — And Their Rivals — A Key Victory

    Novartis stock tumbled Thursday after the firm dropped out of a key cancer treatment race vs. big players Amgen and Bristol Myers Squibb.

  • Yahoo Finance Video

    Novartis raises 2024 profit guidance, stock slipping though

    Swiss pharmaceutical Novartis (NVS) is raising its full-year profit guidance after topping second quarter earnings and revenue estimates. Novartis' stock is slipping lower Thursday morning despite this positive news. Yahoo Finance senior health reporter Anjalee Khemlani details the pharma giant's outlook on its product pipeline as it positions itself more around sales of its heart failure drug Entresto. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Luke Carberry Mogan.